New shot aims to tame COPD Flare-Ups
NCT ID NCT07440524
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests a new biologic drug called JKN24011 in 215 people with moderate to severe COPD. Participants receive either the drug or a placebo as a shot under the skin every four weeks. The main goal is to see if the drug can reduce the number of moderate or severe COPD flare-ups over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JKN24011 (a biologic drug given as a shot under the skin)
- What this could lead to
- If it works, this could lead to a new treatment that reduces flare-ups in people with moderate to severe COPD.
- What could go wrong
- This is an early Phase 2 trial with only 215 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huadong Hospital, Fudan University
Shanghai, 200040, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could remote rehab keep COPD patients out of the hospital?
- Chest vibrations may boost lung sample collection
- Sports-Inspired balance training could help COPD patients avoid falls
- Can remote care tame COPD Flare-Ups?
- Can a biologic clear the clogged airways of COPD?
- Can animated videos boost Self-Care in lung disease better than paper brochures?